IOBTQ — IO Biotech Share News
0.000.00%
Last trade - 00:00NASDAQ RESUMED AT 08:30 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
Brief: Io Biotech Announces Exploration Of Strategic Alternatives
IO Biotech reports $8.4 mln Q3 net loss
Brief: IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
IO Biotech drops after FDA recommends another late-stage study for cancer vaccine
Brief: IO Biotech Provides Update Following Pre-BLA Meeting with FDA
IO Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
IO Biotech Inc expected to post a loss of 36 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Elf Beauty, Intel, Archer Aviation
U.S. STOCKS ON THE MOVE-Duke Energy, Paramount, WW International
IO Biotech drops after cancer vaccine narrowly misses main goal of late-stage study
U.S. STOCKS ON THE MOVE-Bancorp, pot stocks, Avantor
Brief: IO Biotech Announces Clinical Improvement In Progression Free Survival Demonstrated In Pivotal Phase 3 Trial Of Cylembio Plus KEYTRUDA (Pembrolizumab) For The Treatment Of First-Line Advanced Melanoma, But Statistical Significance Narrowly Missed
IO Biotech jumps after cancer vaccine shows promise in late-stage study
IO Biotech's cancer vaccine shows improvement in late-stage study goal (updated)
IO Biotech's cancer vaccines shows improvement in late-stage study goal
IO Biotech Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: IO Biotech Files Prospectus Relates To Resale, From Time To Time For Offering Of Up To 4.2 Million Shares By Selling Stockholders- SEC Filing